The 20 analysts offering 12-month price forecasts for SAGE Therapeutics Inc have a median target of 60.50, with a high estimate of 174.00 and a low estimate of 44.00. The median estimate represents a +53.20% increase from the last price of 39.49.
The current consensus among 22 polled investment analysts is to Buy stock in SAGE Therapeutics Inc. This rating has held steady since November, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.12
Reporting Date Feb 23
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.